雄激素受體在前列腺癌的發(fā)生和發(fā)展中作用明確。臨床上用于治療前列腺癌的藥物為雄激素受體配體結合域的競爭性抑制劑。然而，這類藥物的療效因患者表現(xiàn)出現(xiàn)抵抗而受到限制，導致疾病發(fā)展為去勢抵抗性前列腺癌。近年來靶向雄激素受體N-端結合域或DNA結合域的藥物被報道，這些藥物能夠克服當前藥物治療的缺點，目前正在臨床研究中。對不同靶向的非甾體類雄激素受體的研究進展進行綜述。

The role of androgen receptor in the initiation and progression of prostate cancer is well established. Competitive inhibition of the androgen receptor ligand-binding domain has been employed to combat the disease in clinic. However, their efficacy has often been limited by the emergence of resistance, as a result, leading to disease development for castration-resistant prostate cancer. In recent years, targeting drugs of amino-terminal domain or DNA-binding domain of the androgen receptor have been reported, which can overcome the shortcomings of current drugs, and the clinical research on these drugs is now underway. Research progress on targeted drugs of non-steroidal androgen receptor is reviewed in this paper.

中國醫(yī)學科學院醫(yī)學與健康科技創(chuàng)新工程項目（2016-I2M-3-022、2017-I2M-3-019）